비뇨기과 시장 : 제품 유형, 기술, 질환 유형, 유통 채널, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Urology Market is projected to grow by USD 139.85 billion at a CAGR of 11.74% by 2032.

Urology Market Executive Summary

The urology market is being reshaped by rising disease prevalence, aging populations, and rapid adoption of minimally invasive urology procedures. According to IARC GLOBOCAN 2022, prostate cancer accounted for about 1.47 million new cases worldwide, while bladder cancer exceeded 614,000 new cases and kidney cancer approached 435,000 new cases. These figures reinforce sustained demand for urology diagnostics, endoscopy, robotic surgery, stone management, benign prostatic hyperplasia treatment, urinary incontinence care, and uro-oncology services.

Clinical demand is also expanding beyond cancer. NIDDK reports that benign prostatic hyperplasia becomes increasingly common with age, and kidney stones affect a substantial share of adults, with recurrence risk driving repeat care. For industry leaders, the growth opportunity lies in integrating evidence-based devices, diagnostics, pharmaceuticals, and digital workflows that reduce complications, shorten hospital stays, and improve patient-centered outcomes.

Transformative Shifts in Urology

The urology landscape is shifting from open surgery and episodic care toward minimally invasive, data-enabled, and guideline-directed treatment pathways. Robotic-assisted surgery, flexible ureteroscopy, laser lithotripsy, MRI-targeted prostate biopsy, focal therapies, and outpatient endoscopic procedures are improving precision while helping hospitals manage capacity and cost pressures.

Payment models and regulatory expectations are also changing. Providers and manufacturers are increasingly expected to demonstrate real-world evidence, long-term safety, and measurable quality outcomes. As a result, urology companies that align innovation with clinical guidelines from organizations such as the AUA, EAU, NCCN, and NICE are better positioned to secure adoption, reimbursement, and physician trust.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical enabler in urology rather than a standalone solution. AI-supported imaging review, pathology triage, operative planning, predictive analytics, and remote monitoring are being evaluated to improve diagnostic consistency and workflow efficiency. In prostate cancer, AI applications are most visible in MRI interpretation and digital pathology, where the goal is to reduce variability and support risk stratification.

The cumulative impact of AI will depend on validated datasets, regulatory oversight, cybersecurity, and clinician accountability. FDA guidance on software as a medical device and good machine learning practice indicates that successful AI deployment must be transparent, monitored after launch, and integrated into clinical decision-making without replacing physician judgment.

Key Regional Insights

Asia-Pacific is a high-growth urology region driven by population aging, expanding private hospital networks, and rising diagnosis of prostate, kidney, and bladder conditions. China, India, Japan, South Korea, and Australia are accelerating adoption of endoscopy, laser systems, robotic platforms, and uro-oncology diagnostics, although reimbursement depth and specialist availability vary widely across health systems.

North America remains a leading region for premium urology technologies due to high healthcare expenditure, strong academic medical centers, FDA-regulated innovation, and widespread use of robotic surgery and advanced imaging. Latin America is gaining momentum through private-sector investment and urban specialty centers, with Brazil and Mexico serving as key adoption hubs for minimally invasive urology, kidney stone management, and BPH treatment.

Europe shows steady demand supported by EAU-guided clinical practice, cancer screening discussions, centralized procurement, and growing emphasis on value-based purchasing under the EU Medical Device Regulation. The Middle East, especially GCC countries, is investing in tertiary hospitals, specialty care localization, and medical tourism, while Africa presents long-term demand linked to underdiagnosis, workforce constraints, late-stage cancer presentation, and the need for scalable access to essential urology services.

Key Group Insights

ASEAN markets are benefiting from healthcare infrastructure upgrades, medical tourism, and broader access to endoscopic procedures, with Singapore, Thailand, Malaysia, Indonesia, and Vietnam contributing different levels of purchasing power, clinical capacity, and regulatory maturity. GCC countries are prioritizing advanced hospital capacity, specialty care localization, and digital health infrastructure, making the group attractive for high-value urology devices, robotic surgery programs, and complex uro-oncology services.

The European Union is shaped by harmonized regulatory expectations, health technology assessment, and strong guideline adherence, which favor suppliers with robust clinical evidence, quality systems, and post-market surveillance. BRICS economies offer scale, expanding specialty hospital networks, and rising procedure volumes, but successful access requires localized pricing, service networks, physician training, and public-sector engagement.

G7 countries continue to influence urology clinical standards, reimbursement evidence, screening policy discussions, and early adoption of premium technologies, including robotic-assisted surgery and AI-supported diagnostics. NATO members add importance to supply-chain resilience, cybersecurity, equipment continuity, and trusted digital infrastructure as connected surgical platforms, imaging systems, and remote monitoring tools become more embedded in urology care pathways.

Key Country Insights

The United States leads in robotic urologic surgery, advanced imaging, molecular diagnostics, and clinical trial activity, supported by major academic centers and established reimbursement channels. Canada emphasizes public health system value, evidence-based adoption, and equitable access, while Mexico and Brazil show strong private hospital demand for minimally invasive urology, stone management, and prostate care.

The United Kingdom, Germany, France, Italy, and Spain are influenced by national health technology assessment, EAU-aligned practice, cancer pathway reforms, and growing pressure to reduce waiting lists. Germany and France maintain strong hospital infrastructure and specialist capacity, while the United Kingdom continues to emphasize guideline-based diagnostics, and Italy and Spain show sustained demand for endourology, BPH treatment, and uro-oncology services.

Russia maintains significant demand for urology services despite procurement, reimbursement, and access complexities. China is scaling domestic innovation, hospital modernization, and cancer diagnostics; India is expanding affordable specialty care across metropolitan and tier-two cities; and Japan remains a mature market with aging-driven BPH, incontinence, kidney stone, and cancer demand. Australia and South Korea demonstrate strong adoption of evidence-based technology, with South Korea particularly active in surgical innovation, digital health integration, and high-volume specialty care.

Actionable Recommendations for Urology Leaders

Industry leaders should prioritize clinical evidence, physician education, and total-cost-of-care messaging. Products that reduce length of stay, retreatment, infection risk, radiation exposure, and procedural variability will be better positioned with hospitals, payers, and specialist practices.

Organizations should localize go-to-market models by region, pairing premium platforms with service contracts, training, workflow support, and flexible financing in growth markets. Leaders should also build AI governance, cybersecurity readiness, data interoperability, and post-market evidence systems before scaling connected urology solutions across imaging, surgery, diagnostics, and remote patient monitoring.

Research Methodology

This executive summary is based on triangulation of publicly available and verifiable sources, including WHO and IARC GLOBOCAN cancer statistics, OECD and national health expenditure datasets, FDA and EMA regulatory materials, and clinical guidelines from AUA, EAU, NCCN, and NICE. Peer-reviewed evidence on robotic surgery, MRI-targeted biopsy, stone management, BPH treatment, uro-oncology, and urinary incontinence care was reviewed to identify validated industry drivers.

The methodology emphasizes source reliability, recency, and clinical relevance. Insights were synthesized through epidemiology assessment, regional policy review, technology adoption analysis, reimbursement environment evaluation, and regulatory landscape interpretation to provide decision-useful content for urology stakeholders.

Conclusion

Urology is entering a period of sustained transformation as demographic demand, cancer burden, minimally invasive innovation, and AI-enabled workflows converge. The strongest opportunities will emerge where clinical outcomes, reimbursement evidence, patient access, and operational efficiency are aligned.

Organizations that combine validated technology with regional execution, physician engagement, service reliability, and robust data governance will be best positioned to advance the global urology market while improving quality of care for patients with cancer, kidney stones, BPH, incontinence, and complex urinary disorders.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Urology Market, by Product Type

• 7.1. Disposable Devices
  • 7.1.1. Catheters
    • 7.1.1.1. Foley Catheters
    • 7.1.1.2. Intermittent Catheters
  • 7.1.2. Stents
    • 7.1.2.1. Nephrostomy Stents
    • 7.1.2.2. Ureteral Stents
• 7.2. Reusable Devices
  • 7.2.1. Endoscopes
    • 7.2.1.1. Flexible Endoscopes
    • 7.2.1.2. Rigid Endoscopes
  • 7.2.2. Surgical Instruments

8. Urology Market, by Technology

• 8.1. Imaging Technology
  • 8.1.1. CT Scan
  • 8.1.2. MRI
  • 8.1.3. Ultrasound
• 8.2. Laser Technology

9. Urology Market, by Condition Type

• 9.1. Kidney Stone Disease (Urolithiasis)
• 9.2. Urological Cancers
• 9.3. Benign Prostatic Hyperplasia (BPH)
• 9.4. Urinary Tract Infections (UTIs)
• 9.5. Urinary Incontinence

10. Urology Market, by Distribution Channel

• 10.1. Online
• 10.2. Offline

11. Urology Market, by End User

• 11.1. Ambulatory Surgical Centers
• 11.2. Clinics
• 11.3. Hospitals

12. Urology Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Urology Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Urology Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Ambu A/S
• 16.2. B. Braun Melsungen AG
• 16.3. Baxter International Inc.
• 16.4. Becton, Dickinson and Company
• 16.5. Boston Scientific Corporation
• 16.6. Coloplast A/S
• 16.7. Cook Medical LLC
• 16.8. Dornier MedTech GmbH
• 16.9. EDAP TMS S.A.
• 16.10. Fresenius Medical Care AG & Co. KGaA
• 16.11. Intuitive Surgical, Inc.
• 16.12. Johnson & Johnson Services, Inc.
• 16.13. KARL STORZ SE & Co. KG
• 16.14. Laborie Medical Technologies Corp.
• 16.15. Mediplus Ltd.
• 16.16. Medtronic plc
• 16.17. Olympus Corporation
• 16.18. Promaxo, Inc.
• 16.19. Richard Wolf GmbH
• 16.20. Siemens Healthineers AG
• 16.21. Stryker Corporation
• 16.22. Teleflex Incorporated
• 16.23. Terumo Corporation